中关村(000931.SZ)：胞磷胆碱钠注射液一致性评价申报收到《受理通知书》

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received the Acceptance Notice from the National Medical Products Administration for the consistency evaluation application of Sodium Oligodendrocyte Injection [1] Group 1: Product Information - The Sodium Oligodendrocyte Injection (specification: 2ml:0.25g, calculated as C14H26N4O11P2) was approved for market launch in 1987, with the drug approval number Guoyao Zhunzi H19993355 [1] - The indications for the newly submitted product include: 1) Cerebral blood supply disorders during acute and subacute phases caused by thrombosis or vascular rupture; 2) Conditions resulting from head trauma [1]